Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ChemoMetec ASOCSE:CHEMM -0.32%96 Debt-to-EBITDA is 0.02 as of Dec. 2025, which is 33% below its 10-year median of 0.03. GuruFocus rates OCSE:CHEMM with a GF Score™ of 96/100 and a GF Value™ of kr529.25 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 466 Medical Devices & Instruments companies, ChemoMetec AS ranks better than 98.71% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for ChemoMetec AS's Debt-to-EBITDA or its related term are showing as below:
OCSE:CHEMM'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02 Med: 0.03 Max: 1.42
Current: 0.02
During the past 13 years, the highest Debt-to-EBITDA Ratio of ChemoMetec AS was 1.42. The lowest was 0.02. And the median was 0.03.
OCSE:CHEMM's Debt-to-EBITDA is ranked better than 98.71% of 466
companies
in the Medical Devices & Instruments industry
Industry Median: 1.585
vs OCSE:CHEMM: 0.02
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
ChemoMetec AS Debt-to-EBITDA Related Terms
ChemoMetec AS Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for ChemoMetec AS's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:CHEMM vs ABT, SYK, MDT: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, ChemoMetec AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ChemoMetec AS Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ChemoMetec AS's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ChemoMetec AS's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
ChemoMetec AS (OCSE:CHEMM) has a Debt-to-EBITDA of 0.02 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ChemoMetec AS. This is 33% below median its historical median of 0.03. Over the past decade, ChemoMetec AS's Debt-to-EBITDA has ranged from 0.02 to 1.42. According to the industry distribution chart, ChemoMetec AS ranks #6 out of 466 companies in the Medical Devices & Instruments industry, placing it in the top 1.3%.
Is ChemoMetec AS's Debt-to-EBITDA too high?
ChemoMetec AS's current Debt-to-EBITDA of 0.02 is 33% below median its 10-year median of 0.03. Over the past 10 years, this metric has ranged from a low of 0.02 to a high of 1.42. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.59. ChemoMetec AS's value of 0.02 is 98.7% below this industry median. Based on the distribution chart, ChemoMetec AS ranks #6 out of 466 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ChemoMetec AS has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ChemoMetec AS's Debt-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ChemoMetec AS ranks #6 out of 466 companies for Debt-to-EBITDA. This places ChemoMetec AS in the top 1% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.59. ChemoMetec AS's value of 0.02 is 98.7% below this benchmark. Historically, ChemoMetec AS's own Debt-to-EBITDA has ranged from 0.02 to 1.42 over the past decade. While the company's 10-year median is 0.03 vs. the industry median of 1.59, ChemoMetec AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.59, based on 466 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ChemoMetec AS's current Debt-to-EBITDA of 0.02 is 98.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on ChemoMetec AS. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ChemoMetec AS's current Debt-to-EBITDA is 0.02, which is 33% below median its own 10-year median of 0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ChemoMetec AS stock overvalued right now?
Based on GuruFocus' analysis, ChemoMetec AS (OCSE:CHEMM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr529.25, compared to a current price of kr432.60 — trading 18.3% below its estimated fair value. The current Debt-to-EBITDA is 0.02, which is 33% below median its 10-year median of 0.03 and 98.7% below the Medical Devices & Instruments industry median of 1.59. ChemoMetec AS's overall GF Score™ is 96/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For ChemoMetec AS (OCSE:CHEMM), the current Debt-to-EBITDA is 0.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ChemoMetec AS (OCSE:CHEMM) Overvalued in 2026?
Based on GuruFocus' analysis, ChemoMetec AS stock appears to be undervalued.
The current stock price of kr432.60 is trading 18.3% below its estimated GF Value™ of kr529.25.
GuruFocus considers ChemoMetec AS to be Modestly Undervalued.
Key valuation signals for OCSE:CHEMM:
Debt-to-EBITDA: 0.02 (33% below median its 10-year median of 0.03)
GF Value™: kr529.25 vs. price of kr432.60 (18.3% below fair value)
Industry Position: 98.7% below the Medical Devices & Instruments median (#6 of 466)
No single metric tells the full story. See the OCSE:CHEMM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.
96GF Score
Get the complete analysis for OCSE:CHEMM
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:CHEMM has been successfully added to your 
